MX367850B - Prevención y tratamiento de condiciones inflamatorias. - Google Patents

Prevención y tratamiento de condiciones inflamatorias.

Info

Publication number
MX367850B
MX367850B MX2013015441A MX2013015441A MX367850B MX 367850 B MX367850 B MX 367850B MX 2013015441 A MX2013015441 A MX 2013015441A MX 2013015441 A MX2013015441 A MX 2013015441A MX 367850 B MX367850 B MX 367850B
Authority
MX
Mexico
Prior art keywords
prevention
treatment
inflammatory conditions
embodiments relate
liver disease
Prior art date
Application number
MX2013015441A
Other languages
English (en)
Spanish (es)
Other versions
MX2013015441A (es
Inventor
Kumar Chaturvedi Vipin
Original Assignee
Gri Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gri Bio Inc filed Critical Gri Bio Inc
Publication of MX2013015441A publication Critical patent/MX2013015441A/es
Publication of MX367850B publication Critical patent/MX367850B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203Retinoic acids ; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013015441A 2011-06-24 2012-06-22 Prevención y tratamiento de condiciones inflamatorias. MX367850B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161501139P 2011-06-24 2011-06-24
PCT/US2012/043875 WO2012178108A1 (en) 2011-06-24 2012-06-22 Prevention and treatment of inflammatory conditions

Publications (2)

Publication Number Publication Date
MX2013015441A MX2013015441A (es) 2014-09-22
MX367850B true MX367850B (es) 2019-09-09

Family

ID=47422987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015441A MX367850B (es) 2011-06-24 2012-06-22 Prevención y tratamiento de condiciones inflamatorias.

Country Status (13)

Country Link
US (3) US9949996B2 (https=)
EP (2) EP3616701A1 (https=)
JP (2) JP6441073B2 (https=)
KR (2) KR102055395B1 (https=)
CN (2) CN103732231B (https=)
AU (1) AU2012272642B2 (https=)
BR (1) BR112013033309B1 (https=)
CA (1) CA2840272C (https=)
DK (1) DK2723347T3 (https=)
ES (1) ES2759584T3 (https=)
MX (1) MX367850B (https=)
RU (1) RU2678561C9 (https=)
WO (1) WO2012178108A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012272642B2 (en) 2011-06-24 2017-09-07 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
WO2014113695A1 (en) 2013-01-18 2014-07-24 Cornell University Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
CA2937107C (en) * 2014-01-17 2020-12-22 Cornell University Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションLycera Corporation レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
WO2015138354A1 (en) * 2014-03-10 2015-09-17 Cornell University Combination therapy for head and neck cancer
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションLycera Corporation RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
ES2860823T3 (es) 2014-12-09 2021-10-05 Gri Bio Inc Prevención y tratamiento de afecciones inflamatorias
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
AU2016276947A1 (en) 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
EP3650045B1 (en) 2017-07-04 2024-11-13 Daiichi Sankyo Company, Limited Drug for retinal degenerative disease associated with photoreceptor degeneration
EP3806839B1 (en) * 2018-06-14 2024-08-07 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Retinoic acid receptor-beta2 agonist with cardioprotective effects
US12115140B2 (en) 2020-07-31 2024-10-15 The Trustees Of Columbia University In The City Of New York Method of treating adenoid cystic carcinoma
CN113207799B (zh) * 2021-03-19 2022-03-15 中山大学 一种二型糖尿病小鼠快速心衰模型的构建方法
EP4401829A4 (en) * 2021-09-15 2025-07-16 Univ Cornell COMPOSITIONS AND METHODS FOR ALLEVIATING ALCOHOLIC LIVER DISEASE

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE59777B1 (en) 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicaments
JP3879938B2 (ja) * 1994-03-31 2007-02-14 日本ケミカルリサーチ株式会社 抗炎症剤
JPH08109134A (ja) * 1994-10-11 1996-04-30 Sanwa Kagaku Kenkyusho Co Ltd 細胞変成抑制並びに臓器毒性軽減剤
US6025388A (en) 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
CA2263817A1 (en) * 1996-08-28 1998-03-05 Centre National De La Recherche Scientifique Therapeutic combinations of rar antagonists and rxr agonists and use thereof
DK1051159T3 (da) 1998-01-22 2002-08-05 Zentaris Ag Faste farmaceutiske præparater indeholdende miltefosin til oral administration ved behandling af leishmaniasis
JO2178B1 (en) 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of emphysema using rar selective retinoid antagonists
US7390795B2 (en) 2000-12-18 2008-06-24 Pentraxin Therapeutics Limited Treatment and prevention of tissue damage
EP1372668B1 (en) * 2001-03-26 2011-12-07 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
CA2509955A1 (en) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
US20050026950A1 (en) * 2003-07-30 2005-02-03 Allergan, Inc. Methods of therapeutic treatment using retinoids to achieve consistent bioavailability
CN1210041C (zh) 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗痤疮的复方外用药物
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
US20110118197A1 (en) * 2005-09-29 2011-05-19 Vipin Kumar Chaturvedi Prevention of hepatic ischemic reperfusion injury by administration of sulfatides
DE602006019759D1 (de) * 2005-09-29 2011-03-03 Torrey Pines Inst Sulfatide zur behandlung von autoimmunkrankheiten
JP2009520730A (ja) 2005-12-23 2009-05-28 ヤド・テヒノロギース・ゲーエムベーハー アレルギー性疾患を治療および予防するための手段および方法
DE102006019906A1 (de) 2006-04-28 2007-10-31 Müller-Enoch, Dieter, Prof. Dr. Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptable Salze zur Herstellung einer pharmazeutischen Zubereitung
EP2097075A1 (fr) * 2006-11-20 2009-09-09 Galderma Research & Development, S.N.C. Utilisation d'adapalène pour moduler l'expression de cd1d ou il-10.
CN102595892B (zh) * 2009-07-16 2014-09-10 施泰福实验室股份有限公司 他扎罗汀衍生物
IT1403356B1 (it) 2010-12-27 2013-10-17 Sit La Precisa Spa Con Socio Unico Dispositivo per il controllo dell'erogazione di un gas combustibile verso un bruciatore, particolarmente per apparecchi riscaldatori di acqua
WO2012160186A1 (en) 2011-05-26 2012-11-29 Jado Technologies Gmbh Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
AU2012272642B2 (en) 2011-06-24 2017-09-07 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
US9005490B2 (en) 2012-12-14 2015-04-14 Delphi Technologies, Inc. Material for solid state sintered material
WO2014166941A1 (en) 2013-04-08 2014-10-16 Academisch Medisch Centrum Miltefosin or perifosin for use in the treatment of ibd
ES2860823T3 (es) 2014-12-09 2021-10-05 Gri Bio Inc Prevención y tratamiento de afecciones inflamatorias

Also Published As

Publication number Publication date
KR102055395B1 (ko) 2019-12-12
DK2723347T3 (da) 2019-11-18
EP3616701A1 (en) 2020-03-04
RU2678561C9 (ru) 2019-03-05
RU2014100056A (ru) 2015-07-27
JP2017206523A (ja) 2017-11-24
JP2014517077A (ja) 2014-07-17
CA2840272A1 (en) 2012-12-27
KR102164567B1 (ko) 2020-10-12
CN103732231A (zh) 2014-04-16
CA2840272C (en) 2020-09-15
CN103732231B (zh) 2020-04-10
BR112013033309B1 (pt) 2022-07-05
KR20140048939A (ko) 2014-04-24
US10925886B2 (en) 2021-02-23
BR112013033309A2 (pt) 2017-03-07
EP2723347A4 (en) 2015-02-25
KR20190140087A (ko) 2019-12-18
RU2678561C2 (ru) 2019-01-30
US20180193368A1 (en) 2018-07-12
ES2759584T3 (es) 2020-05-11
US11660309B2 (en) 2023-05-30
MX2013015441A (es) 2014-09-22
US9949996B2 (en) 2018-04-24
EP2723347A1 (en) 2014-04-30
AU2012272642A1 (en) 2014-01-30
US20140187504A1 (en) 2014-07-03
CN111298120A (zh) 2020-06-19
AU2012272642A2 (en) 2014-02-13
EP2723347B1 (en) 2019-09-04
WO2012178108A1 (en) 2012-12-27
AU2012272642B2 (en) 2017-09-07
JP6441073B2 (ja) 2018-12-19
BR112013033309A8 (pt) 2018-03-06
US20210169909A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
MX367850B (es) Prevención y tratamiento de condiciones inflamatorias.
PH12020550764A1 (en) Compositions and methods of use of phorbol esters
IN2014CN03749A (https=)
PH12016501668A1 (en) Compositions and methods for the reduction or prevention of hepatic steatosis
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
IL228297B (en) Oleanen analogs as anti-inflammatory and antioxidant agents
PH12014502603A1 (en) D-amino acid compounds for liver disease
PL2726511T3 (pl) Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych
IN2014CN02736A (https=)
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX2014000142A (es) Uso de anticuerpos agonistas anti-cd83 para tratar enfermedades autoinmunes.
EP2698161A4 (en) MEANS FOR IMPROVING GLUCOSE COMPOUND CHANGING AND COMPOSITION TO IMPROVE GLUCOSE COMPOUND CHANGING
GB2509248A (en) Golf handicap systems and methods to calculate a golf handicap
IN2014DN03464A (https=)
GB2509663A (en) Treatment of adrenal insufficiency
GB201022049D0 (en) Methods
EP2791054A4 (en) RECYCLING OF COPPER INDIUM GALLIUM DISELENID
WO2013033602A3 (en) Fatty acid amides, compositions and methods of use
EP3065705A4 (en) Compositions and methods for administration of an enzyme to a subject's airway
WO2013089809A3 (en) Connectivity of rapidly disseminating epidemics
MX353587B (es) Formulaciones farmacéuticas que contienen ipidacrina y su uso para el tratamiento de trastornos de potencia y trastornos de otras formas de actividad sexual.
UA70732U (en) (±)-cis -3-(2'- benzimidazolyl)-1,2,2-trimethylcyclopentane carboxylic acid hydrochloride exhibiting actoprotective action
HK40021867A (en) Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
MY169285A (en) Enhancement in thermo-chemical formulation
UA65752U (ru) Способ профилактики заболеваний репродуктивных органов у женщин с синдромом поликистозных яичников

Legal Events

Date Code Title Description
FG Grant or registration